Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGIC: Alternating FOLFOX and FOLFIRI in Metastatic GE Cancers
NCT03528876Phase 2Terminated
- Sponsor
- University of Saskatchewan
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan, fluorouracil, folinic acid in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Saskatchewan. Started Sep 2018; status: terminated.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acid
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03528876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528876.